Korea Investment CORP increased its position in shares of Chemours Company (The) (NYSE:CC) by 99.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 162,600 shares of the specialty chemicals company’s stock after buying an additional 81,200 shares during the period. Korea Investment CORP’s holdings in Chemours Company (The) were worth $6,166,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Financial Architects Inc increased its position in shares of Chemours Company (The) by 1,230.3% in the second quarter. Financial Architects Inc now owns 2,940 shares of the specialty chemicals company’s stock worth $111,000 after buying an additional 2,719 shares in the last quarter. Benjamin F. Edwards & Company Inc. increased its position in shares of Chemours Company (The) by 2,138.8% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 3,112 shares of the specialty chemicals company’s stock worth $118,000 after buying an additional 2,973 shares in the last quarter. Ropes Wealth Advisors LLC increased its position in shares of Chemours Company (The) by 82.4% in the first quarter. Ropes Wealth Advisors LLC now owns 3,099 shares of the specialty chemicals company’s stock worth $119,000 after buying an additional 1,400 shares in the last quarter. Schroder Investment Management Group bought a new position in shares of Chemours Company (The) during the first quarter worth about $156,000. Finally, Cypress Capital Management LLC WY increased its position in shares of Chemours Company (The) by 1.9% in the first quarter. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company’s stock worth $162,000 after buying an additional 80 shares in the last quarter. Institutional investors and hedge funds own 75.21% of the company’s stock.

Shares of Chemours Company (NYSE:CC) opened at 44.41 on Friday. Chemours Company has a 52-week low of $11.09 and a 52-week high of $51.51. The firm has a market cap of $8.21 billion, a PE ratio of 29.06 and a beta of 3.63. The stock has a 50 day moving average price of $43.25 and a 200-day moving average price of $37.90.

Chemours Company (The) (NYSE:CC) last posted its earnings results on Wednesday, August 2nd. The specialty chemicals company reported $0.87 EPS for the quarter, beating the consensus estimate of $0.85 by $0.02. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.49 billion. Chemours Company (The) had a return on equity of 122.97% and a net margin of 4.96%. Chemours Company (The)’s revenue for the quarter was up 14.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.27 earnings per share. On average, equities analysts anticipate that Chemours Company will post $3.55 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Thursday, August 17th will be issued a $0.03 dividend. This represents a $0.12 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend is Tuesday, August 15th. Chemours Company (The)’s dividend payout ratio (DPR) is presently 8.11%.

ILLEGAL ACTIVITY WARNING: This story was first reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at https://www.dailypolitical.com/2017/08/11/korea-investment-corp-has-6-17-million-position-in-chemours-company-the-cc.html.

CC has been the topic of a number of analyst reports. ValuEngine upgraded Chemours Company (The) from a “hold” rating to a “buy” rating in a report on Friday, June 2nd. Citigroup Inc. raised their price objective on Chemours Company (The) from $62.00 to $63.00 and gave the stock a “buy” rating in a research report on Monday, April 17th. Jefferies Group LLC reissued a “buy” rating and issued a $48.00 price objective on shares of Chemours Company (The) in a research report on Friday, June 16th. BidaskClub raised Chemours Company (The) from a “hold” rating to a “buy” rating in a research report on Wednesday, July 12th. Finally, Argus reissued a “buy” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Chemours Company (The) in a research report on Thursday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. Chemours Company (The) currently has an average rating of “Buy” and a consensus price target of $51.50.

In related news, insider Paul Kirsch sold 19,036 shares of the stock in a transaction on Monday, June 5th. The stock was sold at an average price of $41.42, for a total value of $788,471.12. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Erich Parker sold 4,908 shares of the stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $45.53, for a total value of $223,461.24. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company’s stock.

Chemours Company (The) Company Profile

The Chemours Company is a provider of performance chemicals. The Company operates through three segments: Titanium Technologies, Fluoroproducts and Chemical Solutions. The Titanium Technologies segment is a producer of titanium dioxide (TiO2). The Fluoroproducts segment is a provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins.

Want to see what other hedge funds are holding CC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemours Company (The) (NYSE:CC).

Institutional Ownership by Quarter for Chemours Company (The) (NYSE:CC)

Receive News & Ratings for Chemours Company (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemours Company (The) and related companies with MarketBeat.com's FREE daily email newsletter.